Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...
Too Old to Operate11h
ACR: Inebilizumab Reduces Risk for Flares in IgG4-Related Disease
according to a study published online Nov. 14 in the New England Journal of Medicine to coincide with the annual meeting of ...
The American Journal of Managed Care12h
New PsA Data Highlight Long-Term Benefits of Bimekizumab
A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...
Lupus Foundation of America17h
Lupus Research Highlights From American College of Rheumatology’s 2024 Scientific Meeting
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
MedPage Today19h
Novel Anti-IgG Drug Hits Mark in Sjogren's Patients
A drug in advanced development for myasthenia gravis also showed promise as a treatment for primary Sjögren's syndrome, a ...
The Pharma Letter20h
Fate Thera rockets on early data for FT819
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
Seeking Alpha23h
Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
Fate Therapeutics driven by positive Phase 1 Autoimmunity study results for its CAR T-cell therapy candidate FT819 in lupus ...